For most deep tech founders, the financing question is not whether to abandon venture capital but which alternative to use at which stage. Three mechanisms dominate the non-VC landscape: government grants, corporate venture capital, and special-purpose acquisition companies. Each occupies a distinct point on the company lifecycle, carries a different dilution profile, and imposes different strategic obligations. The right answer depends on where your technology sits between lab validation and commercial scale, and how much equity you are willing to trade for speed, capital, or market access.
Navigating Deep Tech Funding Beyond Traditional VC
Deep tech's financing problem is structural, not cyclical. As Ovidiu Mihăilă reports for The Recursive, deep tech needs years of capital-intensive development before generating revenue, while most VC funds want proof of market pull within one fund cycle; between the two lies what he calls the valley of death. An IFC, a member of the World Bank Group, financing report maps the full funding spectrum across deep tech stages, from government programs and accelerators at the technology-validation stage through corporate venture capital, IPOs, and SPACs at scale-up and exit. The report also notes that corporations bring advantages beyond capital, including established brands, data, customer relationships, industry partnerships, and captive customer bases. The practical implication is that these mechanisms are complements in a sequence, not substitutes.
Government Grants: Non-Dilutive Capital for Early-Stage De-risking
Grants are the earliest-stage instrument in the set, and their core value is timing rather than size. Used well, per The Recursive's reporting, public deep tech funding is not an alternative to VC but part of a financing sequence that can take a startup to its first institutional round with less risk, less dilution, and a stronger negotiating position. Grant milestones can serve as investor updates and due diligence evidence, and a defensible patent position built during a grant period becomes leverage in later VC negotiations.
Two cautions apply. First, not all public funding is non-dilutive: the EIC's equity component is real equity on market terms, with the EIC Fund as a minority shareholder, and founders should model its dilution and governance rights like any other term sheet. Second, timing matters—evaluation and contracting take months, so a company with six months of cash cannot wait for a grant decision, while one that applies 12 to 18 months ahead can use the grant to shape the round. Reporting from Asia Today, translated by UPI, also captures calls in South Korea to reduce the administrative burdens associated with applying for and settling government grants—a recurring friction point founders should budget for.
Corporate Venture Capital: Strategic Partnerships for Growth
CVC is an equity investment, so it dilutes founders just as traditional venture capital does; the extent depends on the deal structure and valuation. What distinguishes CVC is its objective function. Legal guidance from Morrison Foerster's ScaleUp explains that many CVCs are focused principally on strategic and commercial considerations, with financial returns often secondary, and that a typical CVC strives to gain competitive advantage by identifying technologies that complement its parent company's business through commercial arrangements, partnerships, or acquisitions. Not all CVCs fit this mold—return-driven CVCs behave much like traditional VCs—so each firm's goals and incentives should be evaluated case by case.
The strategic variant can be especially well matched to deep tech. Forbes Councils analysis notes that CVCs now control 47% of all deal value globally, with involvement steady at over 25% of global deals, and that CVCs operate with extended investment horizons compared with traditional VCs' typical 5–7 year timelines—a patience that suits deep tech, healthcare, and climate sectors where innovation cycles exceed traditional VC comfort zones. Adam Miron of Founded Partners frames the trade-off from the founder's side: strategic capital combines equity with a potential commercial contribution such as customer access, distribution, market intelligence, or exit options, whereas financial investors target 3–5x or more returns and assess accordingly.
The IFC report adds a concrete example: Thales's accelerator program offers startups access to its aerospace, space, ground transportation, defense, and security markets free of charge and without equity holding—evidence that corporate partnerships can sometimes deliver market access without dilution at all.
SPACs: A Path to Public Markets for Mature Deep Tech
A SPAC merger is the latest-stage option of the three: a company becomes public by merging with an already-listed shell, rather than through a traditional IPO. Bessemer Venture Partners' State of Deep Tech analysis explains why the vehicle appealed to this sector: investment banks typically want stable cash flows before underwriting a traditional IPO, a preference that challenges early deep tech companies, whereas the SPAC vehicle enabled deep tech companies that had not yet reached commercial scale to raise large amounts of cash and access public markets. That cash, in theory, provides several years of runway and serves as a bridge to profitability, mitigating future financing risk. In 2021, many deep tech companies went public via SPAC mergers.
The dilution is real and structural: the merger process involves issuing new shares to SPAC investors and public shareholders, and the degree of dilution varies with the SPAC's structure and merger terms. A SPAC is therefore a financing and liquidity event for a company with validated technology and a credible path to revenue—not a substitute for the early-stage capital that grants and CVC provide.
Deep Tech Funding Alternatives: A Comparative Framework
The table below compares the three mechanisms across the decision criteria that matter most: stage fit, dilution, and strategic implications. Reading across the rows reveals the pattern: as capital size increases, so does dilution and the maturity required to obtain it.
| Funding Source | Typical Stage | Dilution Impact | Strategic Considerations |
|---|---|---|---|
| Government grants | Early stage—covering the "valley of death" between research and market pull | Generally non-dilutive, though some programs (e.g., the EIC equity component) take real minority equity on market terms | Validation and due-diligence evidence for later rounds; months-long evaluation cycles and administrative burden mean applying 12–18 months ahead |
| Corporate venture capital | Growth and later stage; CVCs drive the largest transactions globally | Dilutive—equity investment like traditional VC; extent depends on deal structure and valuation | Strategic objectives (market access, technology, partnerships) often outweigh financial returns; extended horizons suit long innovation cycles; evaluate each CVC's goals case by case |
| SPACs | Mature ventures approaching public-market readiness | Dilutive—new shares issued to SPAC investors and public shareholders; degree varies with structure and merger terms | Alternative to a traditional IPO when stable cash flows are absent; large cash raise can provide years of runway as a bridge to profitability |
Used this way, the framework lets a founder locate their company on the maturity axis and read off the corresponding trade-off: non-dilutive capital with administrative strings early, strategic partnership capital with equity costs in the middle, and public-market access with structural dilution at the end.
Sequencing Funding: A Strategic Roadmap for Deep Tech Founders
These three mechanisms are not mutually exclusive, and the strongest financing strategies use them in sequence. The typical arc runs: grants first, to de-risk the technology and reduce early dilution while building patent positions and milestone evidence; strategic CVC next, when the technology is validated and market access, distribution, or an extended-horizon partner is worth more than the equity surrendered; and a SPAC or traditional IPO last, once the company can credibly carry public-market scrutiny. The IFC's stage map supports exactly this progression, placing government programs and accelerators at technology validation and first pilots, corporate venture capital and partnerships at commercialization, and IPOs and SPACs at scale-up and exit.
Traditional VC can enter at any point in the middle of that arc—The Recursive's reporting is explicit that public funding works best as a bridge to the first institutional round, not a replacement for it. The sequencing decision is therefore about timing and leverage: each earlier, less dilutive instrument strengthens the negotiating position for the next, more dilutive one.
Making an Informed Funding Decision for Your Deep Tech Startup
Deep tech founders should strategically evaluate alternative funding mechanisms based on their startup's development stage, desired control, and long-term goals, rather than solely relying on traditional VC. This analysis is illustrative rather than exhaustive, and specific terms will vary by deal, jurisdiction, and market conditions—it is not financial advice, and it does not cover the operational or legal steps needed to secure any of these instruments.
The measurable test of whether you have made this decision well is a founder's ability to articulate a clear, sequenced funding strategy that leverages non-dilutive capital for early de-risking and aligns later-stage equity with strategic objectives. If you can state which instrument funds your next 18 months, what equity or governance it costs, and which milestone it positions you for, you have a funding strategy; if you cannot, that gap—not the absence of capital—is the first problem to solve.
Sources
- European Deep Tech Funding: How to Sequence Grants and VC — The Recursive
- Documents1
- UPI
- Ask a MoFo: An Overview of Traditional Venture Capital vs. Corporate Venture Capital — ScaleUp
- Corporate Venture Capital vs. Traditional VC: Strategic Allocation Decisions — Councils
- When to Choose Strategic vs Financial Capital for Growth — Founded Partners
